T-cell receptor alpha-beta complex (TCR) (TCR)

The T-cell receptor (TCR) is a multi-subunit protein complex found on the surface of T lymphocytes, specifically alpha-beta T cells which constitute the majority of the adaptive immune system (Janeway's Immunobiology, 2016). It is responsible for recognizing fragments of antigen as peptides bound to major histocompatibility complex (MHC) molecules, a process that triggers T-cell activation and subsequent immune responses (UniProt P01848). In CD4-positive T cells, the TCR interacts with MHC class II, while in CD8-positive T cells, it interacts with MHC class I (NCBI Gene ID: 6955). This receptor is a critical therapeutic target in oncology, where TCR-engineered T cells (TCR-T) are used to redirect the immune system against intracellular tumor antigens (Nature Reviews Drug Discovery, 2022). Conversely, in autoimmune diseases and organ transplantation, the TCR complex is targeted by monoclonal antibodies like Teplizumab to suppress unwanted immune activation (FDA, 2022). Safety considerations for TCR-directed therapies include the risk of cytokine release syndrome and potential cross-reactivity with healthy tissues (StatPearls, 2023).

Other names

Alpha-beta T-cell receptorTCR alpha/betaTCR-CD3 complexAntigen receptorT-cell antigen receptor

Therapeutic strategies include the use of monoclonal antibodies to bind the CD3 component of the TCR complex, leading to T-cell depletion or modulation of signaling to induce immune tolerance (PubMed: 31209023). In oncology, TCR-engineered T-cell (TCR-T) therapies involve the genetic modification of a patient's T cells to express a specific alpha-beta TCR that recognizes tumor-associated antigens presented by MHC molecules (Nature Reviews Drug Discovery, 2022).